Diuretics: An update on the pharmacology and clinical uses

American Journal of Therapeutics

Volumn 16, Issue 1, 2009, Pages 74-85

  Reddy, Pramod ^a   Mooradian, Arshag D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Aldosterone; Diuretics; Renal physiology; Renin angiotensin

Indexed keywords

ACETAZOLAMIDE; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BUMETANIDE; CHLOROTHIAZIDE; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; INDOMETACIN; LOOP DIURETIC AGENT; MANNITOL; METOLAZONE; NESIRITIDE; OSMOTIC DIURETIC AGENT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE; TRIAMTERENE; UNINDEXED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST;

ALBUMINURIA; ALTITUDE DISEASE; ATAXIA; BARTTER SYNDROME; BLEEDING; CENTRAL PONTINE MYELINOLYSIS; CONFUSION; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DROWSINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG URINE LEVEL; DYSLIPIDEMIA; DYSMENORRHEA; ELECTROLYTE DISTURBANCE; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; GASTRITIS; GITELMAN SYNDROME; GLAUCOMA; GYNECOMASTIA; HEADACHE; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART FAILURE; HENLE LOOP; HUMAN; HYPERALDOSTERONISM; HYPERCALCEMIA; HYPERCHLOREMIC ACIDOSIS; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IDIOPATHIC HYPERCALCIURIA; IMPOTENCE; INAPPROPRIATE VASOPRESSIN SECRETION; INTERSTITIAL NEPHRITIS; INTRACRANIAL HYPERTENSION; KIDNEY; KIDNEY COLLECTING TUBULE; KIDNEY DISTAL TUBULE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; LETHARGY; LEUKOCYTOSIS; LIBIDO; LIDDLE SYNDROME; LIVER CIRRHOSIS; LUNG EDEMA; MASTALGIA; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; METABOLIC DISORDER; NAUSEA; NEPHROLITHIASIS; NEPHROTIC SYNDROME; OTOTOXICITY; PEPTIC ULCER; POLYDIPSIA; POLYURIA; POSTMENOPAUSE BLEEDING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; STOMACH HEMORRHAGE; VOMITING;

ANTIHYPERTENSIVE AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES;

EID: 60249090024     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31818d3f67     Document Type: Review

References (62)

1. Jackson EK. Diuretics. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw Hill; 2006: 737-770.
2. Ives HE. Diuretic agents. In: Katzung BG, ed. Basic & Clinical Pharmacology. 10th ed. New York, NY: McGraw Hill; 2007:236-254.
3. Ellison DH, Wilcox CS. Diuretics. In: Brenner BM, ed. Brenner and Rector's The Kidney. 8th ed. Philadelphia, PA: Sanders Elsevier; 2008:1646-1678.
4. Ix JH, Lingappa VR. Renal disease. In: Mcphee SJ, Ganong WF, S, (eds). Pathophysiology of Disease. An Introduction to Clinical Medicine. 5th ed. New York, NY: McGraw-Hill Professional; 2005:456-481.
5. Scheinman SJ, Guay-Woodford LM, Thakker RV, et al. Genetic disorders of renal electrolyte transport. N Engl J Med. 1999;340:1177-1187.
6. Jackson EK. Renin and angiotensin. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw Hill; 2006:789-822.
7. Connell JMC, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1-20.
8. Kirchner KA, Voelker JR, Brater DC. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int. 1991;40:418-424.
9. Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology. 198;88:261-265.
10. Webster LT Jr, Davidson CS. Production of hepatic coma by a carbonic anhydrase inhibitor diamox. Proc Soc Exp Biol Med. 1956;91:27-31.
11. Shankar SS, Brater DC. Loop diuretics: from the Na-K- 2C1 transporter to clinical use. Am J Physiol Renal Physiol. 2003;284:F11-F21.
12. Dunn CJ, Fitton A, Brogden R. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs. 1995;49:121-142.
13. Voelker JR, Cartwright-Brown D, Anderson S, et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int. 1987;32:572-578.
14. Riser D, Zurbruggen I, Mutschler E, et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int. 1999;55:629-634.
15. Chalasani N, Gorski JC, Horlander JC Sr, et al. Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol. 2001;12:1010-1016.
16. Ribelink TJ, Bijlsma JA, Koomans HA. Iso-oncotic volume expansion in the nephrotic syndrome. Clin Sci. 1993;84: 627-632.
17. Lubetsky A, Winaver J, Seligmann H, et al. Urinary thiamin excretion in the rat: effects of furosemide, other diuretics and volume load. J Lab Clin Med. 1999;134:232-237.
18. Suter PM, Haller J, Hany A, et al. Diuretic use: a risk for subclinical thiamine deficiency in elderly patients. J Nutr Health Aging. 2000;4:69-71.
19. Morrow LE, Grimsley EW. Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. South Med J. 1999;92:866-870.
20. Shimon I, Almog S, Vered Z. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med. 1995;98:484-490.
21. Rose BD, Post TW. Hypoosmolar states-hyponatremia. In: Rose BD, Post TW, eds. Clinical Physiology of Acid Base and Electrolyte Disorders. New York, NY: McGraw-Hill, Inc; 2001:696-745.
22. Puscas I, Coltau M, Baican M. Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25:271-279.
23. Francis GS, Siegel RM, Goldsmith SR. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med. 1985;103:1-6.
24. Daskalopoulos G, Laffi G, Morgan T, et al. Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. Gastroenterology. 1987;92: 1859-1863.
25. Rybak LP, Whitworth C, Scott V. Furosemide ototoxicity is enhanced in analbuminemic rats. Arch Otolaryngol Head Neck Surg. 1993;119:758-761.
26. Rybak L. Ototoxicity of loop diuretics. Otolaryngol Clin North Am. 1993;26:829-844.
27. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross- reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349:1628-1635.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2981-2997.
29. Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29:8-14.
30. Davison JM. Edema in pregnancy. Kidney Int. 1997;51: S90-S96.
31. Fliser D, Schroter M, Neubeck M, et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994;46: 482-488.
32. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J. 2001;22:1343-1352.
33. Messerli FH. Risk factors for renal cell carcinoma: hypertension or diuretics? Kidney Int. 2005;67:774-775.
34. Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology. 1983;84:961-968.
35. Fogel MR, Sawhney VK, Neal EA, et al. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol. 1981;3(Suppl l):73-80.
36. Papadakis MA, Arieff A. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med. 1987;82:945-952.
37. Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994;154:201-205.
38. Pinzani M, Daskalopoulos G, Laffi G, et al. Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. Gastroenterology. 1987;92:294-298.
39. Horisberger JD, Giebisch G. Potassium-sparing diuretics. Ren Physiol. 1987;10:198-220.
40. Stiehm AJ, Mendler MH, Runyon BA. Detection of diuretic-resistance or diuretic-sensitivity by spot urine Na/K ratios. Hepatology. 2002;36:222A.
41. Runyon BA. Refractory ascites. Semin Liver Dis. 1993;13: 343-351.
42. Zannad F, Alia F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700-2706.
43. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
44. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76: 1259-1265.
45. Ramires FJ. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85:1207-1211.
46. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
47. Hall JE, Granger JP. Role of renal hemodynamics and arterial pressure in aldosterone "escape". Am J Hypertens. 1984;6(2 Pt 2):1183-1192.
48. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
49. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
50. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117-123.
51. Coleman CI, Reddy P, Song JC. Eplerenone: the first selective aldosterone receptor antagonist for the treatment of hypertension. Formulary. 2002;37:514-522.
52. Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67:847-858.
53. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005; 111:1487-1491.
54. Gheorghiade M, Gattis WA, O'Connor CM. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA. 2004;291: 1963-1971.
55. Canalese J, Gimson AE, Davis C, et al. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut. 1982;23:625-629.
56. Borges HF, Hocks J, Kjellstrand CM. Mannitol intoxication in patients with renal failure. Arch Intern Med. 1982; 142:63-66.
57. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
58. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
59. Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.J Am Coll Cardiol. 2002;39:798-803.
60. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short- term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.
61. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J. 2006;152:1084-1090.
62. Hernandez AF, O'Connor CM, Starling RC, et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. 2008. (In press).